JPRN-jRCT2080224063已完成2 期
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy
Regeneron Pharmaceuticals, Inc. (Clinical Trial In-Country Representative:PAREXEL International)0 个研究点目标入组 272 人开始时间: 2018年8月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 272
研究概览
简要总结
In this phase 2 trial, use of evinacumab reduced levels of LDL cholesterol and atherogenic lipoproteins in patients with refractory hypercholesterolemia. The response to treatment, or reduction in the LDL cholesterol level, with subcutaneous and intravenous evinacumab was observed as early as the first postbaseline lipid assessment (week 2) and was maintained through week 16.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1.Men and women, ages 18 through 80 at the screening visit
- •2.Diagnosis of primary hypercholesterolemia, either HeFH or non-HeFH with clinical ASCVD
- •3.A history of clinical ASCVD, for those patients who are non-HeFH.
- •4.Receiving a stable maximally tolerated statin (+- ezetimibe) for at least 4 weeks at screening
- •5.For those patients with HeFH who are not receiving a statin at screening, documentation of inability to tolerate at least 2 statins.
- •6.Receiving alirocumab 150 mg SC Q2W, OR evolocumab 140 mg SC Q2W or 420 mg SC Q4W for at least 8 weeks prior to the screening visit
- •7.For those patients with a history of clinical ASCVD, serum LDL-C >= 70 mg/dL at screening (1 repeat lab is allowed)
- •8.For those patients without a history of clinical ASCVD, serum LDL-C >=100 mg/dL at screening (1 repeat lab is allowed)
- •9.Provide signed informed consent
排除标准
- •1.Known history of homozygous FH (clinically, or by previous genotyping)
- •2.Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins
- •3.Newly diagnosed diabetes (within 3 months prior to screening)
- •4.Use of thyroid medications (except for replacement therapy which has been stable for at least 12 weeks before screening)
- •5.Laboratory findings during screening period (not including randomization labs):
- •a.Triglycerides > 400 mg/dL (> 4.52 mmol/L) for patients without a known history of diabetes mellitus; OR Triglycerides > 300 mg/dL (> 3.39 mmol/L) for patients with a known history of diabetes mellitus
- •b.Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody (associated with a positive HCV ribonucleic acid [RNA] polymerase chain reaction)
- •c.Positive serum beta-human chorionic gonadotropin or urine pregnancy test in women of childbearing potential
- •d.Estimated glomerular filtration rate < 30 mL/min/1.73 m^2
- •e.TSH > 1.5 x ULN
- •f.Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN
- •6.Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg at screening visit or time of randomization
- •7.History of heart failure (New York Heart Association [NYHA] Class III-IV) within 12 months before screening
- •8.History of MI, unstable angina leading to hospitalization, CABG surgery, PCI, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, TIA, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease within 3 months prior screening
- •9.History of cancer within the past 5 years (except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer)
- •10.Having received LDL apheresis within 2 months before screening
- •11.Pregnant or breast-feeding women
- •12.Women of childbearing potential who are unwilling to practice a highly effective birth control method
- •13.Men who are sexually active with women of childbearing potential (WOCBP) and are unwilling to consistently use condoms during the study drug treatment period regardless of vasectomy status.
研究者
相似试验
已完成
2 期
Study of Evinacumab (REGN1500) in Participants With Persistent HypercholesterolemiaHypercholesterolemiaNCT03175367Regeneron Pharmaceuticals272
终止
4 期
The CHORAL Flow StudyHyperlipidemiasAtherosclerosisCoronary Artery DiseaseNCT04073134Imperial College London12
终止
3 期
Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With HypercholesterolemiaHypercholesterolemiaNCT00532558Takeda657
已完成
3 期
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular UltrasoundHypercholesterolemiaNCT01813422Amgen970
已完成
3 期
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeCoronary Heart Disease (CHD)NCT03872401Amgen12,301